Table 2.

Hemodynamic monitoring used in selected studies

Study	Device	Hemodynamic targets	Urine output threshold	Intervention
Not targeting urine output in either protocol
Sinclair 1997 [24]	esophageal Doppler	SV		colloids
Polonen 2000 [25]		SvO2, Lactate		fluids, dobutamine, vasoactive medication
Rhodes 2002 [26]	PAC	PAWP		fluid boluses, vasoactive agents
Pearse 2005 [27]	LiDCO plus	SV, DO2I		colloid, dopexamine
Szakmany 2005 [28]	PiCCO	ITBVI		crystalloid, colloid
Wakeling 2005 [29]	esophageal Doppler	SV		colloids
Forget 2010 [30]	Masimo pulse oximeter	PVI		colloids, vasoactive medication
WenKui 2010 [31]		Lactate		crystalloids, colloids, dopamine, ephedrine
Cecconi 2011 [32]	FloTrac/Vigileo	SV		colloids, vasoactive medication, dobutamine
Challand 2012 [33]	esophageal Doppler	SV		colloid
Bartha 2013 [34]	LiDCO	SV, DO2I		fluids, vasoactive medication
Bisgaard 2013 [35]	LiDCO	SVI		colloids, dobutamine, vasoactive medication
Lai 2015 [36]	LiDCO	SVV		Colloids
Targeting urine output only in CFM
Bishop 1995 [37]	PAC	DO2I, VO2I, CI	30-50 ml/h	volume, dobutamine
McKendry 2004 [38]	esophageal Doppler	SI	no specific goal mentioned	colloids, blood, vasoactive medication
Benes 2010 [39]	FloTrac/Vigileo	SVV	0.5 ml/kg/h	colloids, dobutamine
Mayer 2010 [40]	FloTrac/Vigileo	CI, SVI	0.5 ml/kg/h	crystalloids, colloids, norepinephrine, dobutamine, vasodilators
McKenny 2013 [41]	esophageal Doppler	SV	0.5 ml/kg/h	colloids
Zakhaleva 2013 [42]	esophageal Doppler	SV, SVR, CO, FTc	0.5-1.0 ml/kg/h	colloids
Osawa 2016 [43]	LIDCO	CI, SVI	0.5 ml/kg/h	crystalloid, dobutamine
Targeting urine ouput in both protocols
Shoemaker 1988 [44]	PAC	Hct, PvO2, PAP, SVR, PWP, PVR, DO2, VO2	30 mL/h	crystalloids, colloids, vasoactive medication
Boyd 1993 [45]	PAC	DO2I	0.5 mL/kg/h	gelatin, dopexamine
Gattinoni 1995 [46]	PAC	CI or SvO2	0.5 mL/kg/h	fluids, vasoactive medication
Lobo 2000 [47]	PAC	DO2	0.5 mL/kg/h	fluids, dobutamine
Rivers 2001 [48]	computerized spectrophotometer	ScvO2, MAP	0.5 mL/kg/h	crystalloid dobutamine, blood transfusions
Chytra 2007 [49]	esophageal Doppler	SV, FTc	1 mL/kg/h	colloids
Donati 2007 [50]		SvO2, O2ERe	0.5 mL/kg/h	fluids, dobutamine
Kapoor 2008 [51]	FloTrac/Vigileo	CVP, SVV	1 mL/kg/h	colloids, dopamine or other inotropes
Senagore 2009 [52]	esophageal Doppler	SV	0.5 mL/kg/h	colloid
Jammer 2010 [53]		ScvO2	0.5 mL/kg/h	crystalloids, colloid
Jansen 2010 [54]	CeVOX	Lactate, ScvO2	0.5 mL/kg/h	fluids, vasodilator therapy
Jhanji 2010 [55]	LiDCO	SV	25 mL/h	fluids, dopexamine
Bisgaard 2013 [56]	LiDCO	DO2I, SVI	0.5–1.0 mL/kg/h	colloid, dobutamine
Zheng 2013 [57]	FloTrac/Vigileo	CI, SVI, SV	0.5 mL/kg/h	balanced salt solution, colloid, dopamine / norepinephrine, nitroglycerin / ephedrine
Peng 2014 [58]	FloTrac/Vigileo	SVV	0.5 mL/kg/h	Crystalloid, colloid,
Correa-Gallego 2015 [59]	FloTrac/Vigileo	SVV	25 mL/h for 2 consecutive hours	Crystalloid, colloid, albumin bolus infusions

PAC pulmonary artery catheter, PAC+ pulmonary artery catheter with supranormal hemodynamic targets, pre preoperative, intra intraoperative, post postoperative, ICU intensive care unit, ITBVI intrathoracic blood volume index, SV stroke volume, DO ₂ I oxygen delivery index, PAOP pulmonary artery occlusion pressure, CI cardiac index, CO cardiac output, SVR systemic vascular resistance, SVI systemic vascular index, PCWP pulmonary capillary wedge pressure, DO ₂ oxygen delivery, PVI pleth variability index, GEDI global end-diastolic volume index, ELVI extravascular lung water index, SvO ₂ mixed venous oxygen saturation, PAWP pulmonary artery wedge pressure, FTc corrected flow time, PAWP pulmonary artery wedge pressure, SVV stroke volume variation, VO ₂ I oxygen consumption index, SI stroke index, O ₂ ERe oxygen extraction estimate, ScvO ₂ central venous oxygen saturation, CVP central venous pressure, PvO ₂ venous oxygen pressure, PAP pulmonary artery pressure, PWP pulmonary wedge pressure, PVR pulmonary vascular resistance, Hct hematocrit, VO2 oxygen consumption, UO urine output